Engineering Processing Properties of Acetaminophen by Cosolvent Screening - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Engineering Processing Properties of Acetaminophen by Cosolvent Screening
The authors used common solvents to develop an initial solvent-screening method for laboratory-scale research to determine the solubility, polymorphism, and crystal properties of various active ingredients.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 61-68

9. T. Lee and M.S. Lin, Cryst. Growth Des. 7 (9), 1803–1810 (2007).

10. T. Lee and S.T. Hung, Pharm. Technol. 32 (1), 76–95 (2008).

11. T. Lee, S.T. Hung, and C.S. Kuo, Pharm. Res. 23 (11), 2542–2555 (2006).

12. J.C. Burley et al., Eur. J. Pharm. Sci. 31 (5), 271–276 (2007).

13. N. Al-Zoubi, K. Kachrimanis, and S. Malamataris, Eur. J. Pharm. Sci. 17 (1–2), 13–21 (2002).

14. N. Al-Zoubi and S. Malamataris, Int. J. Pharm., 260 (1), 123–135 (2003).

15. P. Di Martino et al., J. Therm. Anal. 48 (3), 447–458 (1997).

16. M. L. Ramos, J.F. Tyson, and D.J. Curran, Anal. Chim. Acta 364 (1–3), 107–116 (1998).

17. R.G. Hollenbeck, J. Pharm. Sci. 69 (10), 1241–1242 (1980).

18. J.W. Mullin, "Solutions and Solubility," in Crystallization, (Butterworth Heinemann, Oxford, UK, 3rd ed., 1992), pp. 93–94.

19. S.H. Yalkowsky, "Solubilization by Cosolvents," in Solubility and Solubilization in Aqueous Media, (American Chemical Society and Oxford University Press, New York, 1999), pp. 180–235.

20. P.W.S. Heng and L.W. Chan, "Drug Substance and Excipient Characterization," in Handbook of Pharmaceutical Granulation Technology, D. M. Parikh, Ed. (Marcel Dekker, New York, 1st ed., 1997), p. 28.

21. M. Kitamura, M. Sugimoto, J. Cryst. Growth 257 (1–2), 177–184 (2003).

22. M. Lahav and L. Leiserowitz, Chem. Eng. Sci. 56 (7), 2245–2253 (2001).

23. B.F. Ruth, Ind. Eng. Chem. Res. 38 (6), 564–571 (1946).

24. E.W. Comings and T.K. Sherwood, Ind. Eng. Chem. Res. 26 (10), 1096–1098 (1934).

25. K. Miyanami, "Mixing," in Powder Technology Handbook, K. Gotoh, H. Masuda, and K. Higashitani, Eds. (Marcel Dekker, New York, 2nd ed., 1997), p. 618.

26. K. Umeya and I. Sekiguchi, J. Soc. Mater. Sci. Japan. 24 (262), 664–668 (1975).

27. B.E. Kurtz and A.J. Barduhn, Chem. Eng. Prog. 56 (1), 67–72 (1960).

28. T. Lee and C.S. Kuo, Pharm. Technol. 30 (3), 110–120 (2006).

29. W. Nernst, Z. Physik. Chem. 47 (1), 52–55 (1904).

30. E. Brunner, Z. Physik. Chem. 47 (1), 56–102 (1904).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here